Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens Research Published on 2022-08-112022-10-05 Journal: Nature Communications [Category] SARS, 치료기술, [키워드] Analysis Antigen BNT162b2 CD4 T-cell CD8 T-cell Cellular immune response ChAdOx1-nCoV-19 Cohort Combination combinations Comparative COVID-19 vaccine FIVE healthy individuals Heterologous highest homologous humoral Immunity induce mRNA-1273 reactogenicity regimen regimens SARS-CoV-2 T-cell the vaccine vaccination Vaccination strategy Vaccine [DOI] 10.1038/s41467-022-32321-0 [Article Type] Research
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialClinical Trial Published on 2022-08-102022-10-06 Journal: The Lancet. Infectious Diseases [Category] SARS, 변종, 진단, [키워드] 1:1 Administered administration adverse event adverse events age amplifying analysed Analysis antibody concentration Antigen assigned available data BMI booster booster dose Breastfeeding Coalition Contraception COVID-19 pandemic diagnosis of COVID-19 dose Efficacy enrolled evaluated event Evidence exclusion geometric mean titre GMT group healthy homologous IgG immune response inactive increase in initial intramuscular Local Matrix-M median Medical conditions Novavax NVX-CoV2373 outcome participant per-protocol per-protocol population phase 2 trial phase 3 study Placebo placebo-controlled pregnant primary endpoint proportion Protein randomisation randomised Randomly reaction reactogenicity receive Recombinant spike protein recruited regimens Registered Safety SARS-CoV SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant screened serum IgG single booster dose stratified Support the SARS-CoV-2 the vaccine titres Treatment Trial USA vaccination Vaccine variant were excluded women [DOI] 10.1016/S1473-3099(22)00420-0 PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV2 mRNA Vaccine-Specific B-, T- and Humoral Responses in Adolescents After Kidney Transplantation신장 이식 후 청소년의 SARS-CoV2 mRNA 백신 특이적 B, T 및 체액 반응Article Published on 2022-08-042022-09-12 Journal: Transplant International [Category] SARS, 진단, [키워드] Adolescent adolescents Adults age analyzed approval Arm B cell B-cell response BNT162b2 CD4 controls cytokine production feature Frequency healthy control Humoral response identify IGD IgG Immunity in both groups kidney kidney transplant recipient Kidney transplantation limitation magnitude majority memory memory cell mRNA neutralizing titers outcome Patient patients Pfizer/BioNTech protection reactogenicity recipients reduced response robust SARS-CoV2 Seroconversion shown significantly Still T cell transplantation Treatment vaccination Vaccines [DOI] 10.3389/ti.2022.10677 PMC 바로가기 [Article Type] Article
Do Side Effects to the Primary COVID-19 Vaccine Reduce Intentions for a COVID-19 Vaccine Booster?1차 COVID-19 백신의 부작용이 COVID-19 백신 부스터에 대한 의도를 감소시키나요?Article Published on 2022-08-022022-09-11 Journal: Annals of behavioral medicine : a publication of t [Category] 변종, [키워드] Administered Analysis booster booster vaccination Booster vaccine conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine dataset demographic factor demographic variable Effect headache Immunity indicated individual intensity Intention Intentions measure National nausea Occurrence pandemic platform positive predict predicted Prolific Psychological reactogenicity receive recruited reduce reduced Regression analyses regression analysis reported Research secondary side Side effect Side effects subsequent Trust vaccination vaccination intention Vaccine Vaccine development variable virus variants Worry [DOI] 10.1093/abm/kaac027 PMC 바로가기 [Article Type] Article
COVID-19 vaccination in pregnancy임신 중 코로나19 예방접종Review Published on 2022-08-012022-09-11 Journal: American journal of obstetrics and gynecology [Category] COVID19(2023년), SARS, 변종, [키워드] abnormality accumulated Admission antibodies benefit country COVID-19 COVID-19 vaccination death Effect effective Ensuring Evidence fetal fetal death fetal morbidity immunization immunogenicity increase in increased risk Infection intensive care intensive care unit admission maternal immunization miscarriage mRNA vaccination mRNA vaccine mRNA vaccines Neonatal Newborn Observational data observational study outcome Oxygenation pandemic Perinatal death potential risk Pregnancy pregnant Preterm birth preterm delivery priority Pulmonary embolism randomized trial randomized trials reactogenicity reduce risk Safe SARS-CoV-2 SARS-COV-2 infection severe SARS severe SARS-CoV-2 Side effects vaccination Vaccine Vaccine hesitancy variants of concern [DOI] 10.1016/j.ajog.2022.05.020 PMC 바로가기 [Article Type] Review
Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study혈액 및 점막의 스푸트니크-V 반응원성과 면역원성: 전향적 코호트 연구Article Published on 2022-08-012022-09-11 Journal: Scientific Reports [Category] SARS, 임상, 진단, 치료기술, 치료법, [키워드] adverse event adverse events alteration assays baseline Blood blood platelet collected condition correlated COVID-19 COVID-19 vaccine COVID-19 vaccines detectable diagnostic dose Effect Efficacy Elevation elicited Gam-COVID-Vac growth Heterologous immune immunization immunology injection Kazakhstan Local Mild-to-moderate mucosal nasal Nasopharyngeal swab nasopharyngeal swabs oncogene outcome participant performed Platelet count populations potentially life-threatening proportion prospective cohort study Questionnaires reactogenic reactogenicity reduced regimen regulated reported SARS-CoV-2 SARS-CoV-2 immunity seroconversion rate Serum level serum levels subject systemic adverse event systemic reactions the vaccine vaccination Vaccine vector Virus neutralization while [DOI] 10.1038/s41598-022-17514-3 PMC 바로가기 [Article Type] Article
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialChAdOx1 nCoV-19 또는 BNT162b2 2회 접종 및 BNT162b2(COV-BOOST) 3차 접종 후 4차 접종으로 제공된 BNT162b2 및 mRNA-1273 COVID-19 백신의 안전성, 면역원성 및 반응성: 다기관, 맹검, 단계 2, 무작위 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 95% CI adverse event All participants analysed anti-spike protein IgG assigned blinded block size BNT162b2 boost booster Booster vaccine cellular Cellular and humoral immunity Cellular immune response ChAdOx1 nCoV-19 computer-generated Concentration Controlled trial country COV-BOOST COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness ELISA ELISPOT Endpoint enrolled fatigue female Fold change Fold changes force geometric geometric mean groups Humoral immunity immunogenicity Intramuscular injection IQR ISRCTN Laboratory Local male median age median interval Moderna modified intention-to-treat mRNA mRNA-1273 mRNA-1273 booster mRNA-1273 COVID-19 vaccine multicentre of BNT162b2 outcome participant peak per-protocol population Pfizer-BioNTech Phase 2 random randomisation list randomised controlled trial Randomised trial Randomly reactogenicity receive Registered reported representing response Safety SARS-CoV-2 screened Serious Adverse Event seronegative participant seronegative participants serostatus Seven significant increase statistician T-cell Response T-cell responses Task Force the vaccine the vaccines titre treatment allocation Trial upper arm Vaccine variant were assessed wild-type [DOI] 10.1016/S1473-3099(22)00271-7 PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study일본 참가자의 S-268019-b 또는 BNT162b2 추가 용량의 면역원성과 안전성: 2/3상, 무작위, 관찰자 맹검, 비열등성 연구의 중간 보고서Clinical Trial Published on 2022-07-302022-09-11 Journal: Vaccine [Category] MERS, 변종, 임상, 진단, [키워드] 95% CI analyzed Anti-spike antibodies BNT162b2 booster booster dose Booster vaccine clinical clinical trial co-primary endpoint co-primary endpoints COVID-19 Delta elicited fatigue Fever geometric mean geometric mean titer GMT GMT ratio immunization immunogenicity Immunoglobulin Immunoglobulin G injection Injection-site pain Interim report Interim result interim results Japanese Live virus MOST myalgia neutralization test Neutralizing antibodies neutralizing antibody observer observer-blinded omicron P-value participant phase 2/3 produced pseudovirus Randomized reactogenicity recombinant Recombinant spike protein regimen reported robust Safe SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event Serious Adverse Events Spike protein subgroups T-cell Response Vaccine variant [DOI] 10.1016/j.vaccine.2022.06.032 PMC 바로가기 [Article Type] Clinical Trial
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trialArticle Published on 2022-07-222022-10-06 Journal: EClinicalMedicine [Category] 진단, [키워드] adverse event adverse events anti-SARS-CoV-2 approach AS03 cellular immunity CEPI clinical study conducted COVID-19 COVID-19 pandemic deviation displaying distribution dose eligible Emergency use enrolled evaluate evaluated flu vaccine foundation geometric mean concentration group groups healthy hospital Humoral immunity IgG antibody immunogenic immunogenicity injection site pain Intervention intramuscularly Investment Local Melinda Gate mitigate myalgia naïve nanoparticle nanoparticle vaccine neutralizing antibody observer-blinded outcome participant per-protocol phase Placebo placebo-controlled primary immunogenicity Protein protocol pseudovirus randomised RBD RBD IgG reached reactogenicity receive recipient Recombinant protein recombinant protein vaccine Registered reported Safety SARS-CoV-2 SARS-COV-2 infection second dose Stage study enrollment Support supported systemic AE systemic AEs T-cell immune responses the receptor-binding domain the vaccine titre Trial vaccination vaccination schedule Vaccine wild-type virus World Health Organization [DOI] 10.1016/j.eclinm.2022.101569 PMC 바로가기 [Article Type] Article
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females남성과 여성에서 ChAdOx1 nCoV-19(AZD1222) 백신에 대한 반응에 대한 탐색적 분석Article Published on 2022-07-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI Academy adjusted age and sex All participant All participants anti-SARS-CoV-2 anti-Spike IgG AstraZeneca AZD1222 both sexes Brazil Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 Chinese clinical Clinical research clinical trials Coalition Council COVID-19 COVID-19 vaccine COVID-19 vaccines defined dose doses Efficacy endpoints Engineering enrolled Evidence evidence of Exploratory analysis fatigue female females Fever first dose Follow-up foundation funding generate GMR greater headache humoral immune responses immunogenicity immunogenicity data immunological individual Innovation interaction term ISRCTN Linear model linear models log-transformed logistic regression models majority male males Medical Science NAAT nCoV network neutralisation assay NIHR no evidence of nucleic acid nucleic acid amplification nucleic acid amplification test Oxford participant Participants primary endpoint randomised randomised controlled trial reaction reactogenicity receive Registered Regression model reported SARS-COV-2 infection Science Sex Sex-differences shown single-blind South spike IgG Standard dose statistically significant difference Superior symptomatic SARS-CoV-2 infection systemic reaction Telle the primary endpoint titre trial participants vaccination Vaccine vaccine efficacy Vaccines Valley Volunteer [DOI] 10.1016/j.ebiom.2022.104128 PMC 바로가기 [Article Type] Article